Novozymes A/S (NSIS-B.CO) Stock

NSIS-B.CO logo

Novozymes A/S

NSIS-B.CODenmark
Non-Energy Raw Materials

Company profile

Novozymes A/S reported revenue of 4.16 billion EUR for fiscal year 2025, up 8.5% from fiscal year 2024, and net income of 583.60 million EUR. That is a net profit margin of 14.0% for fiscal year 2025. In Q3 2026 (the quarter ended September 30, 2026) revenue was 1.14 billion EUR. In Q3 2026 it reported net income of 187.90 million EUR. Our analysis of its filings shows revenue growing from 2.40 billion EUR in fiscal year 2023 to 4.16 billion EUR in fiscal year 2025, 31.6% a year on average. Novozymes A/S reports about 10,933 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Novozymes A/S

Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.

Leadership

  • Ester Baiget — President & CEO, 54
  • Tue Micheelsen — President of Novonesis North America & Head of Global Consumer Health
  • Rainer Lehmann — Executive VP & CFO, 50
  • Anders Lund — Chief Operating Officer, 52
  • Claus Crone Fuglsang — Chief Scientific Officer, 57

How much revenue does Novozymes A/S make?

Novozymes A/S reported 4.16 billion EUR in revenue for fiscal year 2025, up 8.5% from 3.83 billion EUR in fiscal year 2024. In Q3 2026 revenue was 1.14 billion EUR.

How has Novozymes A/S's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 2.01 billion EUR; FY2022, 2.36 billion EUR; FY2023, 2.40 billion EUR; FY2024, 3.83 billion EUR; FY2025, 4.16 billion EUR.

Company Information

SectorNon-Energy Raw Materials
IndustryVarious Advanced Chemical Producers
Employees10,933
HeadquartersLyngby, Denmark
ExchangeCopenhagen
TimezoneEurope/Copenhagen (CET)

Contact & Links

Address
Biologiens Vej 2, Lyngby, 2800
Phone
45 44 46 00 00
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Novozymes A/S (NSIS-B.CO)”, data as of Sep 30, 2026, https://dataporium.tech/stocks/NSIS-B.CO

LinkedInLinkedInXXYouTubeYouTube